<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00113048</url>
  </required_header>
  <id_info>
    <org_study_id>CAM111</org_study_id>
    <nct_id>NCT00113048</nct_id>
  </id_info>
  <brief_title>Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies</brief_title>
  <official_title>A Phase I Study of Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      This phase I study will involve escalating doses of CAMPATH until the goal dose for the&#xD;
      cohort is tolerated. The CAMPATH goal dose will be administered to the patient subcutaneously&#xD;
      (SQ) 3 times per week for up to 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2003</start_date>
  <completion_date>September 2005</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>24</enrollment>
  <condition>Hematologic Malignancies</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAMPATH (alemtuzumab)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with relapsed or refractory hematologic malignancy. The anticipated patient&#xD;
             population are patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's&#xD;
             lymphoma or myeloma&#xD;
&#xD;
          -  Patients with a history of a hematologic malignancy that has previously been shown by&#xD;
             flow cytometry or immunophenotyping analysis to express CD52&#xD;
&#xD;
          -  Any chemotherapy, major surgery or irradiation must have been completed at least four&#xD;
             (4) weeks before enrollment in this study (6 weeks for mitomycin-C or nitrosourea)&#xD;
&#xD;
          -  Patients have recovered from the acute side effects due to prior therapy&#xD;
&#xD;
          -  Life expectancy of &gt; 3 months&#xD;
&#xD;
          -  World Health Organization (WHO) Performance Status 0-2&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Adequate organ function as defined in the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy with CAMPATH&#xD;
&#xD;
          -  Use of an investigational agent within two (2) weeks prior to study enrollment&#xD;
&#xD;
          -  History of anaphylaxis following exposure to humanized monoclonal antibodies&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) positive&#xD;
&#xD;
          -  Prior autologous bone marrow or stem cell transplant if within six (6) months of study&#xD;
             entry&#xD;
&#xD;
          -  A history or prior allogenic bone marrow transplant or organ transplant&#xD;
&#xD;
          -  Known, symptomatic central nervous system (CNS) involvement with lymphoma&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection (excluding skin infection, lower urinary tract infection, or oral&#xD;
             infection), symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>June 3, 2005</study_first_submitted>
  <study_first_submitted_qc>June 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2005</study_first_posted>
  <last_update_submitted>February 4, 2014</last_update_submitted>
  <last_update_submitted_qc>February 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2014</last_update_posted>
  <responsible_party>
    <name_title>Medical Monitor</name_title>
    <organization>Genzyme Corporation</organization>
  </responsible_party>
  <keyword>CD52 Expressing Hematologic Malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

